{"filing":{"accession_number":"0001071739-26-000154","cik":"0001071739","ticker":"CNC","company_name":"CENTENE CORP","form":"8-K","filing_date":"2026-07-27","report_date":"2026-07-28","primary_document":"cnc-20260728.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1071739/000107173926000154/cnc-20260728.htm"},"events":[{"id":20820,"run_id":18739,"accession_number":"0001071739-26-000154","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"summary":"Centene Corporation issued a press release on July 28, 2026, announcing second quarter 2026 financial results, including GAAP diluted EPS of $2.19, adjusted diluted EPS of $2.51, and increased full-year 2026 guidance (GAAP diluted EPS greater than $3.11 and adjusted diluted EPS greater than $4.80), with comprehensive financial metrics and segment performance.","company_name":"CENTENE CORP","ticker":"CNC","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":20298,"accession_number":"0001071739-26-000154","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"Centene Corporation issued a press release on July 28, 2026, announcing second quarter 2026 financial results, including GAAP diluted EPS of $2.19, adjusted diluted EPS of $2.51, and increased full-year 2026 guidance (GAAP diluted EPS greater than $3.11 and adjusted diluted EPS greater than $4.80). The disclosure includes comprehensive financial metrics, segment performance, membership data, and forward guidance, which is the hallmark of a quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:05:13.901645+00:00","company_name":"","ticker":null,"filing_date":""},{"id":20300,"accession_number":"0001071739-26-000154","item_number":"7.01","item_title":"REGULATION FD DISCLOSURE","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a press release announcing Centene Corporation's second quarter 2026 financial results, including GAAP diluted EPS of $2.19, adjusted diluted EPS of $2.51, and increased full-year 2026 guidance (GAAP diluted EPS greater than $3.11 and adjusted diluted EPS greater than $4.80). The disclosure includes detailed revenue, membership, and operational metrics across business segments, making it a standard quarterly earnings release material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:05:13.901645+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":20821,"run_id":18739,"accession_number":"0001071739-26-000154","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The Board elected Paul Diaz as a director effective July 28, 2026, to fill the vacancy created by Kenneth Burdick's resignation, and assigned him to the Audit Committee and Quality and Compliance Committee. Diaz brings substantial healthcare executive experience as former CEO of Myriad Genetics and Kindred Healthcare.","company_name":"CENTENE CORP","ticker":"CNC","filing_date":"2026-07-27","form":"8-K","submitted_at":null,"items":[{"id":20299,"accession_number":"0001071739-26-000154","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02(d) disclosure centers on the Board's election of Paul Diaz as a director effective July 28, 2026, to fill the vacancy created by Kenneth Burdick's resignation. While Burdick's departure is mentioned, the principal action disclosed is Diaz's appointment to the Board and his assignment to the Audit Committee and Quality and Compliance Committee. His substantial healthcare executive background (former CEO of Myriad Genetics and Kindred Healthcare) makes this a material board composition change.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:05:13.901645+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20298,"accession_number":"0001071739-26-000154","item_number":"2.02","item_title":"RESULTS OF OPERATIONS AND FINANCIAL CONDITION","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"Centene Corporation issued a press release on July 28, 2026, announcing second quarter 2026 financial results, including GAAP diluted EPS of $2.19, adjusted diluted EPS of $2.51, and increased full-year 2026 guidance (GAAP diluted EPS greater than $3.11 and adjusted diluted EPS greater than $4.80). The disclosure includes comprehensive financial metrics, segment performance, membership data, and forward guidance, which is the hallmark of a quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:05:13.901645+00:00","company_name":"CENTENE CORP","ticker":"CNC","filing_date":"2026-07-27"},{"id":20299,"accession_number":"0001071739-26-000154","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02(d) disclosure centers on the Board's election of Paul Diaz as a director effective July 28, 2026, to fill the vacancy created by Kenneth Burdick's resignation. While Burdick's departure is mentioned, the principal action disclosed is Diaz's appointment to the Board and his assignment to the Audit Committee and Quality and Compliance Committee. His substantial healthcare executive background (former CEO of Myriad Genetics and Kindred Healthcare) makes this a material board composition change.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:05:13.901645+00:00","company_name":"CENTENE CORP","ticker":"CNC","filing_date":"2026-07-27"},{"id":20300,"accession_number":"0001071739-26-000154","item_number":"7.01","item_title":"REGULATION FD DISCLOSURE","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a press release announcing Centene Corporation's second quarter 2026 financial results, including GAAP diluted EPS of $2.19, adjusted diluted EPS of $2.51, and increased full-year 2026 guidance (GAAP diluted EPS greater than $3.11 and adjusted diluted EPS greater than $4.80). The disclosure includes detailed revenue, membership, and operational metrics across business segments, making it a standard quarterly earnings release material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T10:05:13.901645+00:00","company_name":"CENTENE CORP","ticker":"CNC","filing_date":"2026-07-27"}]}